Have been reading on a variety of groups about Zudaifu cream, and whether or not this contains steroids.  When I asked my Dermatologist he said all non-regulated creams contain steroids - it's the only way they work.  I've only met my Dermatologist three times and trying to be nice, he doesn't really have a personality and one of the old-school consultants who quite possibly has a god-complex!  So I'm looking for some user experience. 

I'm flummoxed - listed below the ingredients for Zudaifu cream, I can't figure out which is the steroid - can someone enlighten me? 

Ingredients: Sophorae Flavesgentis radix (anti-inflammatory Chinese medicinal herb), Stermonae radix (antibacterial and antifungal Chinese medicinal herb), Cnidii Fructus (Chinese medicinal herb that kills parasites), Kochiae Fructus (Chinese medicinal herb used to clear heat and remove dampness), Menthae Haplocalycis herb (Chinese medicinal herb for rashes), Extracts, Chlorhexidine acetate (skin cleanser for wounds), Stearic Acid, Distilled Monostearate, Glycerol Vineargear, Petrolatum, Purified Water.

Thanks!
Catherine

Hi every one! So I am new here and I wanted to get some feedback on taltz. I just started the injections yesterday and it hurt so bad :( do these injections ever stop hurting? I mean I'll take the pain to get rid of the painful psoriasis but these shots are no joke. Thanks!

Hello,
I've been reading posts on here for maybe a couple months and am finally doing my introduction.
I was born w/psoriasis. I turned 50 yesterday. I've had psoriatic arthritis about 10 yrs but didn't realize that's what it was. 
I've been trying to manage it all with diet and lifestyle, also tanning beds. However, the progression of symptoms made me realize I could no longer manage this horrible disease on my own.
Skipping ahead, my dermatologist got me samples of Cosentyx in hopes it would be approved by my insurance but they want me to try Humira first.
My first loading does of Cosentyx began on 8/24/18 and did all 5 weeks before the insurance denial. I did just 150 mg instead of 300 mg.
My psoriasis started clearing so quickly. It was amazing. It didn't do anything noticeable for the psoriatic arthritis. No noticeable side effects.
I will be starting Humira, assuming all goes as planned. I hear Humira works pretty well for psoriatic arthritis and I'm trying to ignore the negative stuff I read about it.
This forum seems amazing. 
Nancy Mullendore

My sons neck has been stiff for months. Our doctor said he guaranteed it was not related to psoriatic arthritis, and the dermatologist said yesterday that psoriatic arthritis is usually in the hands so its unlikely related. Anyone here ever had issues with the neck and arthritis?

hi im yato, 13 had psoriasis since i was like 6?? it started on my scalp and gradually went down into my eyebrows but never progressed further until about 5 years later. now its all over my body (at least 50-60%) and i have no pill/shot i can take since i'm not 18 yet. 

the only medicated thing i can use is one of those weak steroid creams, but those have proven ineffective as there isn't enough for me to use it on a regular basis. 

has anyone ever tried regular gold bond lotion (the healing kind), for me it's pretty effective. though it doesnt make it go away super fast, it lessens the impact on my daily life + it doesn't cling to my skin like some other medicated creams. 

okay im going on a tangent but hello!!

Had a few days where we basically pretended Psoriasis was a not a thing in our lives.  It was blissful but now I am crashing. The face P is the most crushing. Getting closer to going the Stelera route but he is just so young ? I been looking for info on Elidel as a doctor friend told me it could be be good. I can’t  find anything on here.  Has anyone here tried it?

Hi All-

Have had severe psoriasis for about 15 years.  Started around the age of 35 or so.  Tried a bunch of steroid ointments which helps minimally.  I was my derms first patient for biologics many years ago.  I believe it was Enbrel.  Can't remember I've gone through so many.  Most of them work for me for a couple of years, then start to lose their effects.  Start to see positive results in a few weeks, then about 4 months for about 80-90% clearances.

After Enbrel, started Humira, then Stelara, then Cosentyx.  Cosentyx worked for about 3 years until the beginning of this year.  Was about to start Taltz, but my derm said I could try Humira again since Taltz doesn't work too well, from his experience.  Went back on Humira for a couple of months, but didn't see any improvement this time around.

My derm suggested I try giving my body a break from the biologics.  So after a few weeks of weening myself from those, and my psoriasis flaring up like crazy...worst I've ever experienced because I've always had the various drug treatments, I started on Otezla(oral pill). 

Well, about 4 weeks into Otezla, I became severely allergic.  I mean, rashes and bumps all over my body.  The itchiest experience you can imagine.  Many, many times worse than any psoriasis itchiness I've experienced.  

I ended taking over 100mg of Claritin a day for 3 weeks.  And of course, immediately stopped taking the Otezla.  Had to rid my system of all traces, so went cold turkey without any psoriasis meds for another couple of months, so you can imagine how bad the psoriasis became.

Anyhow, started on Siliq about a month ago and the results are promising.  Truth be told, other than the Humira on the 2nd round, all the injection treatments have worked pretty well.  I just hope Siliq works as well as the others in clearing up my condition.  And, that it continues to work for years to come or until another (or better) solution is developed.

Thanks for reading and letting me share my experience.

day one on shooting the med up. How long before it works if it works.Thanks

Doc proscribed CLobex foam for a few days on the scalp. Pharmacist (Chemist to most of you) said there isn't a foam, so I have to choose between shampoo and spray. Whats the difference? Is there one more terrible than the other, or more effective?

Hi,

I registered On Friday and activated my account through email. It's not letting me access my own profile saying I don't have permission. Does it just take a while or should I be doing something?

Many thanks,

Kath

Had an appointment with the GP today. He suggests trying a round of phototherapy before trying Stelera.  A gentler treatment and if it works and the P doesn’t come back- awesome! If it does come back, nothing lost and THEN we try Stelera. Makes good sense I think.  What are your experiences with phototherapy?

Hi. So great to hear about this group and to read the various threads-they are of great comfort to me and are also so informative. Thank you. 

 My daughter (18) has extensive guttate P on her body, legs and arms and plaque P on her scalp. 

She has been on treatment for the last 18 months with no change at all to her P-in fact it has become worse. 
She is on the maximum dosage of methotrexate that our doctor is comfortable with and also has topical creams-  dovobet,diprosalic, various tar products, clobex shampoo(which gives her painful hairline acne if used for too long. ) I am probably forgetting a host of other potions and lotions. 

The reason I am posting is that I feel that this way of treatment has gone on too long and it's time for a change. Our dermatologist agreed and has given us various options: acitretin, cylocsporin, phototherapy or one of the Biologics. He is getting back to me on more information about each drug. 
Any advice? I have read some of the threads on Stelera and it seems very positive. 

My question I guess is:-what would the recommendation be from anyone who has walked this road before?
I find it really hard making a decision for my child when all of the drugs have such serious side effects. 
I look forward to any thoughts or suggestions. Many thanks.

This study looked at the prevalence and incidence of psoriasis and psoriatic arthritis over time in Ontario, Canada.

Quote:

---

Objective:
To estimate the prevalence and incidence of psoriasis and psoriatic arthritis (PsA) over time in Ontario, Canada.

Methods:
We performed a population‐based study of Ontario health administrative data using validated case definitions for psoriasis and PsA. We computed the crude and age/sex‐standardized cumulative prevalence and incidence of psoriasis from 2000 to 2015.

Results:
Among the 10,774,802 individuals aged 20 years and older residing in Ontario in 2015, we identified 273,238 and 18,655 patients with psoriasis and PsA, respectively, equating to cumulative prevalence estimates of 2.54% and 0.17%, respectively. Correcting the prevalence estimates for imperfect sensitivity and specificity resulted in similar estimates. The male‐to‐female ratio was approximately 1.0 for both conditions. For psoriasis, the age/sex‐standardized cumulative prevalence increased from 1.74% in 2000 to 2.32% in 2015. For PsA, the age/sex‐standardized cumulative prevalence increased from 0.09% in 2008 to 0.15% in 2015. Between 2008 and 2015, annual incidence rates for psoriasis decreased, whereas those for PsA remained relatively stable.

Conclusions:
The prevalence and incidence of psoriasis and PsA in Ontario are similar to those observed in Europe and the United States. The steady increase in the prevalence of psoriasis and PsA over the past decade may be due to a combination of population aging, population growth, and increasing life expectancy.

I found this interesting as I no longer bother filling a Dermatology Life Quality Index (DLQI) at my dermatology appointments as I find none of the questions relevant.

Quote:

---

Background:
The Dermatology Life Quality Index (DLQI) is the most frequently used health‐related quality of life (HRQoL) instrument for skin diseases. According to the DLQI instructions the responses “not relevant” and “my skin problem has not at all affected this aspect of life” (“not at all”) have to be scored as 0 = no HRQoL impairments.

Objective:
The aim of this study was to estimate potential bias of DLQI measurements for patients with psoriasis based on items considered to be not relevant.

Methods:
1,243 patients with psoriasis were surveyed in a cross‐sectional study. Disease severity (PASI) and subjective health state (EQ VAS) were compared per DLQI item between patients who answered the respective question “not relevant” and those who answered “not at all”.

Results:
Patients who declared a DLQI item to be not relevant showed a higher disease severity and a lower health state.

Conclusion:
Results indicate that patients who declare a DLQI item to be not relevant have a higher disease related burden than those who do not feel affected by their psoriasis in the same aspect of life. If aspects of life are considered to be not relevant due to high disease burden this should be reflected by a HRQoL instrument.

Hi. I’m Jo and I’ve just joined this forum. I was diagnosed with psoriasis in January 2018 after 6 months of not really knowing what was happening (to my scalp especially). Got nowhere with GP so paid £180 to see a private consultant dermatologist who made the diagnosis in 30 minutes. Prescribed Sebco, Betamousse, Alphosyl shampoo and Eumovate. However, I haven’t really seen any real  improvement. Returned to GP who, after telling me that I’m “an unfortunate case” prescribed Dobovet which actually started to help but now my hair is falling out and I’ve got bald patches!! It’s  really affecting my confidence. Anyone got any ideas?

How long do you try treatments before deciding they are not working? My son's scalp psoriasis is suddenly quite bad, worse since starting with the extra strength tgel shampoo, but also in the same week as starting tgel had a very stressful event, and ate unusually poorly for a week so I am not sure what caused the flare up.  He was diagnosed with Glutate about 6 months ago and proscribed clobetasol which worked with in 2 weeks (but it all came back and more). Now 2 weeks seems to be my marker for 'working'. Tried to switch from Clobelosol to Dovobet but saw little result in 3 weeks so stopped. We have an appointment to see the dermatologist in 4 weeks, but he is really pushing the Biologics and my son is only 13 so I think much to young for such a treatment. I would love to calm that scalp down (and the rest of his P) but don't know when to give up on a treatment and try something else.

Hi I am new to this forum. I do not have psoriasis but my 13 year old son does. I am quite active on a couple other sites and am always looking for and researching best treatments for him. I would like to treat him as holistically as possible. We use clobetosol but of course a soon as we stop his P flares up and I do not want him to spend his life on steroids not do I want to compromise his immune system more than it already is with Biologics. That said his mental health is of utmost importance so if we need to do those things we will. He does have small amounts of P all over most of his body.

Sienna Biopharmaceuticals remain excited about their Phase 2 studies beginning in the second half of 2019 of SNA-125 in Psoriasis.

Quote:

---

Sienna Biopharmaceuticals a clinical-stage medical dermatology and aesthetics company, today announced results from a first-in-human study of its investigational new chemical entity SNA-125, a JAK3/TrkA inhibitor being evaluated as a first-in-class topically administered medication to treat mild-to-moderate psoriasis.

SNA-125 was developed using Sienna’s Topical by Design™ platform, which yields new chemical entities (NCEs) designed to deliver high local drug concentration in the target tissue with minimal to no systemic exposure for patients. SNA-125 selectively inhibits Janus kinase 3 (JAK3) and tropomyosin receptor kinase A (TrkA). JAK3 inhibition blocks the signaling of key cytokines, resulting in reduced severity of certain autoimmune and inflammatory diseases such as psoriasis. TrkA is the high-affinity receptor for nerve growth factor (NGF), a known mediator of neurogenic inflammation associated with psoriasis, as well as pruritus (itch).

This exploratory Phase 1/2, double-blind, within-subject vehicle-controlled study in 15 subjects, using a psoriasis microplaque model, was designed to measure an effect on inflammatory skin infiltrate thickness, local tolerability, and histology and biomarkers with two doses of SNA-125 prototype gel applied once daily for 10 days.

In this model, SNA-125, the second NCE from Sienna’s Topical by Design™ platform, was well-tolerated and showed no safety signals. Neither dose of SNA-125 (0.2 or 2 percent) reduced the inflammatory skin infiltrate thickness from baseline (p>0.8). However, histological and biomarker analyses showed a modest, statistically significant reduction with SNA-125 0.2 percent in epidermal thickness from baseline (-17%, p<0.05), as well as modulation of certain psoriasis-relevant biomarkers and gene expression profiles.

“This exploratory study, while limited, showed a modest drug effect and good tolerability with SNA-125, and provides us with directional information to help guide the design of our Phase 2 development program,” said Frederick C. Beddingfield III, MD, PhD, President and Chief Executive Officer of Sienna Biopharmaceuticals. “Of course, we would have liked to have seen more robust impact in this early-stage model, but treatment with SNA-125 may take longer than ten treatments to reveal its full effect. In parallel with this study, we have developed a more optimal cream formulation to treat inflammatory skin disorders that is undergoing nonclinical testing, and we remain excited about our Phase 2 studies beginning in the second half of 2019. We look forward to additional data from our Topical by Design™ platform in the fourth quarter of 2018 – namely, our SNA-125 Phase 1/2 study in atopic dermatitis, as well as our SNA-120 Phase 2b study in pruritis associated with psoriasis, now that enrollment has been completed ahead of schedule.”

This could be interesting for the future. An IL-17A inhibitor as a topical or pill for treating psoriasis.

Quote:

---

Nuevolution announced the identity of its “Cytokine X” program being a lead discovery program targeting inhibition of Interleukin IL-17A using small molecules. Nuevolution’s small molecules may offer access to both topical (e.g. cream based) treatment as well as safe tablet-based treatment, whereas currently marketed IL-17A inhibitors are injectable and high-cost antibodies that come with potential adverse reactions from the treatment. The company also announced that it will initiate promotion for potential partnership opportunities on this exciting program targeting multiple inflammatory diseases.

IL-17A is the founding signalling cytokine produced from TH17 cells of the immune system. This cytokine is responsible for driving multiple inflammatory diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis and is considered a major contributing factor in diseases such as inflammatory bowel disease and multiple sclerosis. The IL-17A target has presented itself as a very challenging protein to inhibit (block) with small molecules, and presently all available inhibitors are therefore based on injectable antibodies.

Through application of Nuevolution’s Chemetics® platform, trillions of molecules were screened against IL-17A. This was followed by application of Nuevolution’s powerful drug discovery optimization platform leading to identification of very potent small molecule lead compounds that directly and selectively bind the human IL-17A protein and potently block IL-17A cell signaling to human keratinocytes (skin cells). In order to validate the mechanism of action and benchmark our IL-17A blockers, we recently demonstrated that one of our small molecule lead compounds was as effective as an IL-17A neutralizing antibody in a collagen-induced arthritis (CIA) in vivo mouse model.

In our program, X-Ray crystallography (three-dimensional structures) from multiple chemical series have shown compounds bound to the IL-17A target illustrating distinct mechanisms of IL-17A binding of each chemotype. This supports our lead optimization efforts further towards the potential identification of a program candidate. Our data also supports that a small molecule directly targeting IL-17A, may achieve the same efficacy in clinical scoring as a therapeutic antibody directed against IL-17A.

Our current optimization efforts focus on finalizing data for initially a potential topical use of our IL-17A blockers as well as seeking a potential next generation systemic (tablet-based) formulation with the ambition of achieving a first-in-class small molecule candidate for both topical and systemic treatment options.

The development of an innovative topical as well as tablet-based small molecule program, targeting the IL-17 pathway, would be of very high value especially in diseases like psoriasis, psoriatic arthritis as well as other inflammatory diseases. Global Data is forecasting global sales in each of these indications reaching about USD 13 billion in 2024 and 2025 respectively, which underlines the interest and need for innovative treatment options in inflammatory diseases.

“Important and disease relevant protein-protein interfaces, like the one we target here in our IL-17A program, are notoriously difficult to inhibit with small molecules. We are very enthusiastic about this unique program and believe it has a strong potential to deliver a potential first-in-class small molecule drug for topical and tablet-based use directly targeting IL-17A”, said Thomas Franch, CSO.

Hey everyone.

33 year old male, have had psoriasis for the last 15+ years, just a patch on each elbow and calf, until this year, when i got my first flare....my legs are currently covered, my arms are very sore, getting patches on my scalp and my back and my torso.

Currently healing a broken toe, and have to have a TB test, and once this is out of the way i'll be starting Stelara.

Looking forward to really getting this under control.